Yoda Program Opens in 2026: Investigating Digestive Cancer Rejuvenation
- THE DAILY: What is the reality of the progression of digestive cancers in adults under 50?
- DR. FABRICE BARLESI: By 2030, 11% of colon cancers and 23% of rectal cancers will occur in patients under 50 (1), while gastrointestinal cancers will become the second...
- All studies converge to show that there is indeed an increase in the incidence of these "early-onset cancers," including a 2025 study (2).
THE DAILY: What is the reality of the progression of digestive cancers in adults under 50? Can we talk about an ”emerging epidemic” of these young cancers?
DR. FABRICE BARLESI: By 2030, 11% of colon cancers and 23% of rectal cancers will occur in patients under 50 (1), while gastrointestinal cancers will become the second leading cause of cancer-related mortality. For the population under 50 affected by cancer, projections indicate that the global number of new cases and deaths will increase by 31% and 21% respectively by 2030, a large part of this increase being attributable to gastrointestinal cancers.
All studies converge to show that there is indeed an increase in the incidence of these “early-onset cancers,” including a 2025 study (2). Epidemiological data, mainly from North America, indicate an increase in several types of cancers, including breast, thyroid, but also digestive cancers. Globally, the number of new cancer diagnoses in those under 50 has increased by about 80% in less than three decades, from 1.82 million cases in 1990 to 3.26 million in 2019 (3). This trend is also observed in France, with an increase in digestive and breast cancers, first observed in a French study of 15-39 year olds. Published in March 2025, the results of the EPI-AJA 2022 project (4) revealed a continued increase in the incidence of six types of cancers between 2000 and 2020: colorectal carcinomas (+1.43% per year on average), breast cancers (+1.60%), kidney cancers (+4.51%), Hodgkin’s lymphomas (+1.86%), glioblastomas (+6.11%) and liposarcomas (+3.68%).
For us at Gustave Roussy, this awareness came from observing a rejuvenation of patients admitted to the digestive oncology department. is there a real trend, or is it just chance? For now, we do not yet have solid national data, as there is no dedicated registry, its creation having been voted last year. Still, we are seeing a numerical increase - which remains fortunately small – but, proportionally, the increase is significant for digestive tumors in peopel under 40 or 50, depending on the studies. In 2022,according to the globocan 2022 survey,there were nearly 6,000
olique,dont le rôle est reconnu notamment dans les cancers digestifs ainsi que dans les cancers du sein) et la sédentarité (9). Par ailleurs, certaines études suggèrent l’impact d’une dysbiose du microbiote intestinal (10). Par exemple, le cancer colorectal chez le sujet jeune est souvent associé à un enrichissement en taxons pro-inflammatoires et génotoxiques (par exemple, Fusobacterium nucleatum, Escherichia coli productrice de colibactine, Bacteroides fragilis entérotoxigène) et à une diminution des commensaux producteurs d’acides gras à chaîne courte.Les analyses multiomiques révèlent des signatures hôte-microbiome distinctes, influencées par la prédisposition génétique, l’immunité muqueuse, le sexe et les expositions précoces, possiblement en lien avec une utilisation plus fréquente d’antibiotiques pendant l’enfance, dans les générations récentes par rapport aux précédentes.
L’alimentation est également mise en cause : des données américaines nombreuses indiquent que la consommation d’aliments ultra-transformés serait davantage associée au cancer colorectal et du pancréas chez ces jeunes patients (11). Il ne s’agit que d’hypothèses, car les preuves mécanistiques formelles font encore défaut à ce jour.
Yoda concernera des patients âgés de 20 à 49 ans diagnostiqués d’un cancer digestif localisé ou métastatique. Des prélèvements variés seront réalisés : sang, graisse, cheveux, tissus néoplasiques et autres, dans le but d’étudier les expositions potentielles auxquelles ces patients ont pu être soumis. Le type d’exposition que nous pourrons identifier à partir des prélèvements collectés permettra de rechercher d’éventuelles signatures biologiques témoignant d’expositions ou de modifications spécifiques liées à certains facteurs environnementaux (air, eau, sols…). Sur le plan toxicologique, nous étudierons notamment la présence de pesticides et de microplastiques, ces derniers représentant une exposition émergente susceptible d’expliquer certaines pathologies cancéreuses. Nous aborderons cette analyze sans a priori, en explorant toutes les pistes possibles, qu’il s’agisse de signatures particulières ou de modifications associées à des expositions. Nous générerons ensuite des signatures clinicomiques, capturant les interactions complexes entre les facteurs cliniques, moléculaires, environnementaux et nutritionnels.
Les inclusions vont débuter en 2026, et le projet vise à finaliser le recrutement et la collecte des données d’ici 2029, soit sur une
okay, I will follow your instructions precisely. Here’s the output, adhering to the constraints and phases you’ve outlined. I will prioritize verification and avoid any mirroring of the provided source.
“`html
Rising Incidence of Early-Onset Cancers
Table of Contents
There has been a documented increase in the incidence of several cancers, including colorectal, pancreatic, and biliary tract cancers, among younger adults (typically defined as under 50 years old).
This trend deviates from the historical pattern where cancer diagnoses were primarily concentrated in older populations. Several factors are being investigated as potential drivers of this increase, including lifestyle changes, environmental exposures, and alterations in the gut microbiome. The reasons for this rise are complex and likely multifactorial, making it a significant public health concern.
Such as, a study published in JNCI Cancer Spectrum in 2018 linked sedentary behavior and increased television viewing time to a higher risk of young-onset colorectal cancer.Nguyen LH,et al. JNCI Cancer Spectr. 2018 Nov;2(4):pky073
Colorectal Cancer in Younger Adults
Early-onset colorectal cancer (EOCRC), defined as diagnosis before age 50, is increasing in incidence globally.
Historically, colorectal cancer was largely a disease of older adults. Though, rates are now rising considerably in younger individuals. This shift is prompting discussions about earlier screening recommendations and a re-evaluation of risk factors. Changes in diet, specifically increased consumption of ultra-processed foods, and alterations in the gut microbiome are being actively researched as contributing factors.
A 2025 study in JAMA Oncology found a correlation between ultraprocessed food consumption and the risk of colorectal cancer precursors among women. Wang C, et al. JAMA oncol. 2025 Nov 13:e254777
Pancreatic and Biliary Tract Cancers in Younger Populations
Similar to colorectal cancer, there is growing evidence of an increasing incidence of pancreatic and biliary tract cancers in individuals under the age of 50.
These cancers are often diagnosed at later stages in younger patients, possibly contributing to poorer outcomes.Research is ongoing to identify specific risk factors and develop targeted prevention strategies. The increasing burden is prompting inquiry into potential environmental and genetic predispositions.
A review published in ESMO Gastrointestinal Oncology in September 2025 highlighted the rising incidence and explored risk factors for early-onset pancreatic and biliary tract cancers. Boilève A, et al. ESMO Gastrointestinal Oncology, Volume 9, September 2025. Further research published in 2025 in JHEP Reports focused specifically on young-onset biliary tract cancers, examining characteristics, treatment patterns, and patient outcomes. Pudlarz T, et al.JHEP Rep. 2025 aug 11;7(11):101550
The Role of the Gut Microbiome
The gut microbiome is increasingly recognized as a potential contributor to the development of early-onset colorectal cancer.
Dysbiosis, an imbalance in the gut microbial community, has been observed in individuals with EOCRC. Specific microbial signatures may be associated with increased risk or disease progression. research is exploring the potential for targeted interventions, such as dietary modifications or fecal microbiota transplantation, to modulate the gut microbiome and prevent or treat EOCRC.
A 2025 publication in Journal of Personalized Medicine detailed distinct gut microbiome signatures in early-onset colorectal cancer and discussed potential therapeutic strategies. Lauricella S, et al. J Pers Med. 2025 Nov 12;15(11):552
Breaking News Check (as of 2026/01/15 00:28:06): As of this date, there have been no major, confirmed breaking developments significantly altering the understanding of these trends beyond the research published in late 2025. Ongoing research continues to